Overview

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

Status:
Completed
Trial end date:
2017-04-12
Target enrollment:
Participant gender:
Summary
This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
Phase:
Phase 2
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Liraglutide